Forte Biosciences, Inc. (FBRX)

Forte Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	30.44	37.13	41.1	42.04	58.77	6.94
Cash & Cash Equivalents	30.44	37.13	41.1	42.04	58.77	6.94
Cash Growth	-15.20%	-9.67%	-2.25%	-28.45%	746.88%	-92.78%
Other Current Assets	1.06	1.2	0.41	0.48	1.13	0.57
Total Current Assets	31.5	38.33	41.51	42.52	59.9	7.51
Property, Plant & Equipment	0.11	0.11	0	0	0.1	0.15
Other Long-Term Assets	0.41	0.54	0.49	0.79	1.24	0
Total Long-Term Assets	0.52	0.65	0.49	0.79	1.34	0.15
Total Assets	32.02	38.98	42	43.31	61.24	7.66
Accounts Payable	1.69	1.42	1.15	0.95	1.24	1.57
Other Current Liabilities	1.65	2.24	2.03	0.81	1.02	0.34
Total Current Liabilities	3.33	3.67	3.18	1.76	2.26	1.91
Other Long-Term Liabilities	0	0	0	0	0	10.52
Total Long-Term Liabilities	0	0	0	0	0	10.52
Total Liabilities	3.33	3.67	3.18	1.76	2.26	12.43
Retained Earnings	-125.94	-118.52	-87.04	-73.17	-51.46	-4.97
Comprehensive Income	-0	0	0	0	0	0
Shareholders' Equity	28.69	35.31	38.82	41.55	58.98	-4.77
Net Cash / Debt	30.44	37.13	41.1	42.04	58.77	6.94
Net Cash / Debt Growth	-15.20%	-9.67%	-2.25%	-28.45%	746.88%	-90.07%
Net Cash Per Share	0.66	1.18	2.36	3.01	7.99	3.29
Working Capital	28.17	34.66	38.33	40.76	57.64	5.59
Book Value Per Share	0.62	1.12	2.23	2.98	8.02	-2.26

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).